Published in Blood on August 21, 2003
Mast cells and mastocytosis. Blood (2008) 2.32
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood (2005) 1.83
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res (2008) 1.39
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol (2014) 1.14
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia (2015) 0.95
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia (2015) 0.93
Mastocytosis. Immunol Allergy Clin North Am (2013) 0.89
Pharmacological treatment options for mast cell activation disease. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.87
Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica (2013) 0.86
Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia (2015) 0.85
Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol (2006) 0.84
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Res (2017) 0.83
Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive. Case Rep Hematol (2012) 0.80
Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res (2013) 0.80
Severe chronic diarrhea and maculopapular rash: a case report. World J Gastroenterol (2011) 0.80
H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol (2010) 0.78
Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia. Br J Haematol (2014) 0.78
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J (2011) 0.77
NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. Allergy (2012) 0.77
A Case of Intestinal Mastocytosis Misdiagnosed as Crohn's Disease. Case Rep Gastroenterol (2015) 0.75
Mastocytosis 2016: Updated WHO Classification and Novel Emerging Treatment Concepts. Blood (2016) 0.75
Hypotension, Syncope, and Fever in Systemic Mastocytosis without Skin Infiltration and Rapid Response to Corticosteroid and Cyclosporin: A Case Report. Case Rep Med (2010) 0.75
Systemic Mastocytosis with Associated Clonal Hematological Non-Mast Cell Lineage Disorder (MDS-RCMD): A Difficult Disease to Diagnose and Treat. Indian J Hematol Blood Transfus (2015) 0.75
Systemic mastocytosis with associated acute myelogenous leukemia. Proc (Bayl Univ Med Cent) (2014) 0.75
Versatile synthesis and biological evaluation of novel 3'-fluorinated purine nucleosides. Beilstein J Org Chem (2015) 0.75
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis (2005) 3.96
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood (2009) 3.47
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol (2009) 3.38
Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis (2009) 3.33
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med (2015) 3.18
Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation (2014) 2.16
Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma (2008) 2.12
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood (2002) 2.01
The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res (2004) 1.58
Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer (2009) 1.56
Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. Blood (2013) 1.49
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol (2006) 1.48
Elevated levels of D-dimer and fragment 1+2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis. Haematologica (2005) 1.47
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol (2010) 1.46
The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood (2012) 1.46
Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphoma. Leuk Lymphoma (2008) 1.43
Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice. Leuk Lymphoma (2012) 1.42
Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria. J Infect Dis (2007) 1.42
The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost (2005) 1.39
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol (2010) 1.38
[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging (2003) 1.35
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood (2005) 1.35
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica (2008) 1.33
Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood (2004) 1.30
An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood (2009) 1.27
ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria. Am J Trop Med Hyg (2009) 1.27
Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol (2006) 1.24
Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood (2008) 1.24
C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization. Ann Thorac Surg (2005) 1.23
Mastocytosis in children: a protocol for management. Pediatr Dermatol (2008) 1.20
FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2013) 1.17
The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol (2007) 1.16
Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost (2006) 1.13
Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol (2009) 1.11
JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood (2011) 1.09
(18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med (2009) 1.09
Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol (2014) 1.09
Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. AJR Am J Roentgenol (2011) 1.07
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood (2010) 1.07
A male with angioimmunoblastic T-cell lymphoma and proliferative glomerulonephritis. Ann Hematol (2004) 1.06
Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy. Br J Haematol (2010) 1.04
Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica (2011) 1.02
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res (2012) 1.02
Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost (2002) 0.99
Determination of no-observed-adverse-effect levels and eliciting doses in a representative group of peanut-sensitized children. J Allergy Clin Immunol (2006) 0.98
False-positive Aspergillus galactomannan antigen test results. Clin Infect Dis (2004) 0.98
Imbalance of angiopoietin-1 and angiopoetin-2 in severe dengue and relationship with thrombocytopenia, endothelial activation, and vascular stability. Am J Trop Med Hyg (2012) 0.98
T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. Haematologica (2009) 0.96
Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci (2005) 0.95
Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol (2005) 0.95
Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging (2003) 0.94
Lipid transfer protein-linked hazelnut allergy in children from a non-Mediterranean birch-endemic area. J Allergy Clin Immunol (2007) 0.94
Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13. PLoS Negl Trop Dis (2012) 0.94
Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol (2014) 0.92
Plasma concentration of von Willebrand factor predicts mortality in patients on chronic renal replacement therapy. Nephrol Dial Transplant (2011) 0.92
Increased intima-media thickness after early-onset preeclampsia. Obstet Gynecol (2006) 0.92
Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol (2009) 0.91
Levels of extra domain A containing fibronectin in human atherosclerotic plaques are associated with a stable plaque phenotype. Atherosclerosis (2007) 0.91
Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma (2013) 0.90
Hodgkin lymphoma: Response assessment by revised International Workshop Criteria. Leuk Lymphoma (2007) 0.90
beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood (2007) 0.90
On the added value of baseline FDG-PET in malignant lymphoma. Mol Imaging Biol (2009) 0.89
Endothelial cell activation and hypercoagulability in ocular Behçet's disease. Am J Ophthalmol (2004) 0.88
Extra-domain-A fibronectin: a new marker of fibrosis in cutaneous graft-versus-host disease. J Invest Dermatol (2004) 0.88
Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis. J Crohns Colitis (2010) 0.88
Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: comparison with CT in a prospective multicenter study. J Magn Reson Imaging (2013) 0.88
Activation of hemostasis after coronary artery bypass grafting with or without cardiopulmonary bypass. Anesth Analg (2004) 0.87
Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET. Eur J Nucl Med Mol Imaging (2010) 0.87
Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation. Clin Infect Dis (2010) 0.86
Platelet activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as biomarkers. PLoS One (2013) 0.86
Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases. Leuk Lymphoma (2013) 0.85
IL-18 serum concentration is markedly elevated in acute EBV infection and can serve as a marker for disease severity. J Infect Dis (2012) 0.85
Endothelial cell activation after subarachnoid hemorrhage. Neurosurgery (2002) 0.85
The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder. Haematologica (2012) 0.85
Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. Am J Hematol (2011) 0.84
Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study. Leuk Lymphoma (2011) 0.84
Magnetic resonance imaging of malignant lymphoma. Expert Rev Hematol (2011) 0.84
Internet use for health information among haematology outpatients: a cross-sectional survey. Inform Health Soc Care (2011) 0.84
Clinical reactivity to hazelnut in children: association with sensitization to birch pollen or nuts? J Allergy Clin Immunol (2006) 0.83
ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphoma: feasibility study. MAGMA (2010) 0.83
Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability. Leuk Res (2005) 0.82
Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause. Ann Hematol (2007) 0.82
Bone marrow biopsy in diffuse large B-cell lymphoma: useful or redundant test? Acta Oncol (2014) 0.82
Hazelnut allergy: from pollen-associated mild allergy to severe anaphylactic reactions. Curr Opin Allergy Clin Immunol (2008) 0.82
Decreased arterial elasticity in formerly early-onset preeclamptic women. Acta Obstet Gynecol Scand (2011) 0.81
Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy. J Magn Reson Imaging (2013) 0.81
Parental anxiety before and after food challenges in children with suspected peanut and hazelnut allergy. Pediatr Allergy Immunol (2009) 0.81
Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur Radiol (2013) 0.81
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol (2013) 0.81
Whole-body magnetic resonance imaging, including diffusion-weighted imaging, for diagnosing bone marrow involvement in malignant lymphoma. Br J Haematol (2010) 0.81
Physical activity and physical fitness in lymphoma patients before, during, and after chemotherapy: a prospective longitudinal study. Ann Hematol (2013) 0.80